Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer

Inclusion Criteria: * Signed informed consent prior to beginning protocol specific procedures. * 18 years * Radiologically proven presence of metastases * Histologically/cytologically proven prostate adenocarcinoma. * Biochemically evaluable disease * Patients must have received prior hormonal therapy as defined below: * Castration by orchiectomy and/or LHRH agonists with or without * Antiandrogens * Other hormonal agents (e.g., ketoconazole, ...) * The testosterone level should be \< 50 ng/dl (10) documented disease progression defined by PSA increase. Patients must have a value of at least 5 ng/ml in addition to increasing PSA to be eligible. * Life expectancy \> 3 months * ECOG performance status 0-2. * Normal cardiac function. Exclusion Criteria: * Prior chemotherapy except estramustine phosphate. * Prior isotope therapy (e.g., strontium, samarium). * Prior radiotherapy to \>25% of bone marrow * Prior therapy with anti-VEGF therapy * Prior malignancy except the following: adequately treated basal cell or squamous cell skin cancer, or any other cancer from which the patient has been disease-free for \>5 years. * History or presence of central nervous system (CNS) disease (i.e. primary brain tumor, malignant seizures, CNS metastases or carcinomatous meningitis) * Symptomatic peripheral neuropathy * Other serious illness or medical condition the use of corticosteroids. * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening. * Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BAY 9006. * Major surgery with 4 weeks of study entry * Autologous bone marrow transplant or stem cell rescue within 4 months of study entry * Use of biologic response modifiers, such as G-CSF, within 3 weeks of study entry * Treatment with any other anti-cancer therapy (except LHRH agonists) including any prescribed compounds and/or OTC products for the treatment of prostate cancer must be stopped. * Treatment with drugs that are metabolized by the cytochrome P450 system (i.e warfarin sodium,…) * Treatment with systemic corticosteroids used for reasons other than specified by the protocol must be stopped. * Biphosphonates could not be initiated after inclusion into the protocol. At inclusion, patients receiving biphosphonates with a PSA progression could continue biphosphonates. * Patients with reproductive potential not employing an effective method of birth control. Barrier contraceptives must be used throughout the trial. * Inadequate recovery from previous surgery, radiation, chemo-, biologic or immunotherapy * Patients who have known hypersensitivity to the study medication * Substance abuse, medical social, psychological conditions that may interfere with the subject's participation in the study or evaluation of study results * Patients unable to sallow oral medications.